PharmaShots | Incisive News in 3 Shots

Subscribe Now

Eosinophilic Esophagitis (EoE)

Takeda Reports the US FDA's Acceptance of NDA for TAK-721 (budesonide oral suspension) to Treat Eosinophilic Esophagitis

Takeda Reports the US FDA's Acceptance of NDA for TAK-721 (budesonide oral suspension) to Treat Eosinophilic Esophagitis

December 16, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us